

Foreign Governments Undervalue Chronic Disease Medicines According to U.S. Physicians



Importing European-style price controls through a Most Favored Nation (MFN) or similar policy could allow the government to override doctor decisions and restrict patient access to medicines in the U.S.



According to 100 surveyed U.S. physicians, Germany **drastically undervalues** the clinical benefit of innovative medicines in chronic diseases

The **vast majority** of these physicians indicated innovative medicines offer **additional clinical benefit** beyond negative German benefit assessments in:



Asthma
94%

indicated additional clinical benefit




COPD
99%

indicated additional clinical benefit








Diabetes
98%

indicated additional clinical benefit



Importance of Patient-Centered Factors when Assessing a Medicine's Value

Patient-centered factors – which are typically devalued in government value assessments – are rated as very important by most U.S. physicians:

	Asthma	COPD	Diabetes
 Unmet needs	92%	92%	84%
 Frequency of administration	90%	92%	88%
 Maintains ability of patient/caregiver to work	90%	86%	96%
 Ability to extend life until next treatment	88%	82%	86%
 Route of administration	86%	90%	80%